Seyrantepe Volkan, Hinek Aleksander, Peng Junzheng, Fedjaev Michael, Ernest Sheila, Kadota Yoshito, Canuel Maryssa, Itoh Kohji, Morales Carlos R, Lavoie Julie, Tremblay Johanne, Pshezhetsky Alexey V
Department of Medical Genetics, CHU Sainte Justine Research Center, University of Montreal, Montreal, Quebec, Canada.
Circulation. 2008 Apr 15;117(15):1973-81. doi: 10.1161/CIRCULATIONAHA.107.733212. Epub 2008 Apr 7.
Lysosomal carboxypeptidase, cathepsin A (protective protein, CathA), is a component of the lysosomal multienzyme complex along with beta-galactosidase (GAL) and sialidase Neu1, where it activates Neu1 and protects GAL and Neu1 against the rapid proteolytic degradation. On the cell surface, CathA, Neu1, and the enzymatically inactive splice variant of GAL form the elastin-binding protein complex. In humans, genetic defects of CathA cause galactosialidosis, a metabolic disease characterized by combined deficiency of CathA, GAL, and Neu1 and a lysosomal storage of sialylated glycoconjugates. However, several phenotypic features of galactosialidosis patients, including hypertension and cardiomyopathies, cannot be explained by the lysosomal storage. These observations suggest that CathA may be involved in hemodynamic functions that go beyond its protective activity in the lysosome.
We generated a gene-targeted mouse in which the active CathA was replaced with a mutant enzyme carrying a Ser190Ala substitution in the active site. These animals expressed physiological amounts of catalytically inactive CathA protein, capable of forming lysosomal multienzyme complex, and did not develop secondary deficiency of Neu1 and GAL. Conversely, the mice showed a reduced degradation rate of the vasoconstrictor peptide, endothelin-1, and significantly increased arterial blood pressure. CathA-deficient mice also displayed scarcity of elastic fibers in lungs, aortic adventitia, and skin.
Our results provide the first evidence that CathA acts in vivo as an endothelin-1-inactivating enzyme and strongly confirm a crucial role of this enzyme in effective elastic fiber formation.
溶酶体羧肽酶,组织蛋白酶A(保护蛋白,CathA),是溶酶体多酶复合物的一个组成部分,与β-半乳糖苷酶(GAL)和唾液酸酶Neu1一起,在其中它激活Neu1并保护GAL和Neu1免受快速的蛋白水解降解。在细胞表面,CathA、Neu1和GAL的无酶活性剪接变体形成弹性蛋白结合蛋白复合物。在人类中,CathA的遗传缺陷导致半乳糖唾液酸贮积症,这是一种代谢性疾病,其特征是CathA、GAL和Neu1联合缺乏以及唾液酸化糖缀合物的溶酶体贮积。然而,半乳糖唾液酸贮积症患者的一些表型特征,包括高血压和心肌病,不能用溶酶体贮积来解释。这些观察结果表明,CathA可能参与了超出其在溶酶体中的保护活性的血液动力学功能。
我们构建了一种基因靶向小鼠,其中活性CathA被活性位点带有Ser190Ala取代的突变酶所取代。这些动物表达生理量的无催化活性的CathA蛋白,能够形成溶酶体多酶复合物,并且没有出现Neu1和GAL的继发性缺乏。相反,这些小鼠显示血管收缩肽内皮素-1的降解速率降低,动脉血压显著升高。CathA缺陷小鼠在肺、主动脉外膜和皮肤中也显示弹性纤维缺乏。
我们的结果提供了首个证据,表明CathA在体内作为一种内皮素-1失活酶发挥作用,并有力地证实了该酶在有效弹性纤维形成中的关键作用。